Heron Therapeutics Inc

-0.07 (-2.22%)
Other Pre-Announcement

Heron Therapeutics Qtrly Loss Per Share $0.63

Published: 05/09/2022 22:18 GMT
Heron Therapeutics Inc (HRTX) - Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates.
As of March 31, 2022, Heron Had Cash, Cash Equivalents and Short-term Investments of $111.9 Million.
Expect Net Cash Used for Operating Activities of $37 Million to $39 Million in Q2 of 2022.
Sees FY Revenue $89 Million to $93 Million for Oncology Care Franchise.
FY2022 Revenue View $122.6 Million -- Refinitiv Ibes Data (analyst estimates).
Qtrly Basic and Diluted Net Loss per Share $0.63.
Q1 Earnings per Share View $-0.48 -- Refinitiv Ibes Data (analyst estimates).